Aldehyde dehydrogenase-2 is a host factor required for effective bone marrow mesenchymal stem cell therapy.
From the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases (Hongming Zhu, A.S., Hong Zhu, Z.H., S.Z., X.M., Y.Z., K.H., J.G.), Biomedical Research Center (Z.L.), Zhongshan Hospital, and Institute of Biomedical Science (H.Z.), Fudan University, Shanghai, China.
- Published Article
Arteriosclerosis Thrombosis and Vascular Biology
Ovid Technologies Wolters Kluwer -American Heart Association
- Publication Date
Apr 01, 2014
Our study establishes ALDH2 as a key mediator of host stem cell niche for optimal MSC therapy and suggests that ALDH2 deficiency present in the general population is a limiting host factor to be considered for MSC therapy.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/24558108